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Abstract
Background:  Concerns have recently been raised about the negative effects of patents on
innovation. In this study, the effects of patents on innovations in the Korean biotech SMEs (small
and medium-sized entrepreneurs) were examined using survey data and statistical analysis.
Results: The survey results of this study provided some evidence that restricted access problems
have occurred even though their frequency was not high. Statistical analysis revealed that difficulties
in accessing patented research tools were not negatively correlated with the level of innovation
performance and attitudes toward the patent system.
Conclusion: On the basis of the results of this investigation in combination with those of previous
studies, we concluded that although restricted access problems have occurred, this has not yet
deterred innovation in Korea. However, potential problems do exist, and the effects of restricted
access should be constantly scrutinized.
Background
In a knowledge-based economy, it is assumed that the pat-
ent system is an effective incentive mechanism for
research and development (R&D), particularly in fields
such as biotechnology where innovations have long gesta-
tion periods. However, the patent system is an imperfect
mechanism because privatization can mitigate these ben-
efits [1]. Recent studies have suggested that too much pat-
enting could potentially deter innovation [1-6]. Concerns
about over-patenting and its negative effects are wide-
spread [2], which has prompted researchers to investigate
the effects of patents [7-17]. Many of these studies have
focused on the field of biotechnology in particular [7-13].
The "upstream" patents in this field have enormous
power because inventions cannot be invented around (see
Note A) and are of crucial importance to researchers [10].
Heller and Eisenberg argued that biomedical innovation
has become susceptible to a so called "tragedy of the anti-
commons," which can emerge when each of the multiple
owners of innovations has a right to exclude others from
a scarce resource [1,7]. Under these circumstances, trans-
action costs become too high to collect all the relevant
information for further research, which results in an
under use of patented biotechnological information [1,2].
Shapiro also raised similar concerns, where he referred to
this phenomenon as the "patent thicket." He argued that
technologies that depended on the agreement of multiple
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parties were susceptible to delay by any one member
[6,7]. Indeed, there has been some evidence that broad
foundational patents can "block" research pathways [7].
In addition, it may stifle or misdirect research and retard
the development of socially beneficial products and proc-
esses [2].
Empirical investigations in the US have also confirmed
the existence of access problems, especially for upstream
discoveries. Cho et al. conducted a survey of clinical labo-
ratory directors who performed DNA-based genetic tests
to examine the potential effects of patents. The respond-
ents reported that their perceptions of the effects of pat-
ents on the cost, access, and development of genetic tests
or data sharing among researchers were negative [8]. In
addition, Thumm's survey, conducted in Switzerland, also
confirmed that the concepts of anticommons, patent
thickets, and royalty stacking were of practical relevance
[2]. The NRC (National Research Council) provided a
series of case studies on the use of patents, which covered
a small number of important research tools (especially
foundational upstream discoveries), and found that
"restricted access" to upstream discoveries and tools had
occurred [5]. Murray and Stern constructed a set of 169
patent-paper pairs from the US and a control group com-
prising non-patent-paper pairs. The pattern of forward
citations to scientific articles of the patent-paper pairs was
then compared with that of the control group. On the
basis of this analysis, it was shown that after the patent
grant was issued, the citation rate of the related paper
declined by between 9% and 17%, indicating that a mod-
est anticommons effect occurred [9].
Walsh et al. conducted 70 interviews with several different
innovation entities (ie, pharmaceutical firms, biotech
firms, university researchers, technology transfer officers,
patent lawyers, etc). In contrast to other studies, they
observed less breakdown or restricted access to research
tools than expected [7]. They argued that some related
problems (for example, royalty stacking, expensive licens-
ing fees for tools, etc.) were manageable and that the ben-
efits were larger than the costs. Nicol and Nielsen (2003)
conducted a survey and a number of interviews in Aus-
tralia, and the participants reported that they had rarely
experienced difficulties in accessing broadly applicable
research tools and technologies [11]. In an IPI (Intellec-
tual Property Institute) study carried out in the UK,
respondents answered that the patent thicket had not
materialized and that "they did not feel that genetic
sequence patents had had a negative impact on R&D"
[12]. Resnik (2001) examined the current climate of DNA
patents and concluded that the benefits outweigh the
drawbacks [13]. According to an AAAS (American Associ-
ation for the Advancement of Science) survey, only 11%
of Japanese scientists reported some difficulties in acquir-
ing patented technology in the past five years [15]. Fur-
thermore, Azoulay et al. examined the effects of the
patenting behavior of academic life scientists in a panel
dataset and found that both the flow and stock of the sci-
entists' patents were positively related to their subsequent
publication record. The positive correlation between pat-
ent applications and the flow of publications suggests that
patents and papers encode similar pieces of knowledge,
and patents do not crowd out the level of scientific publi-
cations [16,17].
In summary, the effects of patents on subsequent innova-
tions in the field of biotechnology are still unclear in
developed countries. It is important to investigate the
effects of prior patents on innovation in developing coun-
tries because innovations in these countries are usually
incremental or follow-on innovations. In this study, the
effects of patents, especially research tool patents (see
Note B), on innovation were examined using survey data
and statistical analysis.
Methods
A survey of researchers in the biotechnology industry was
conducted between March and April 2008. The sample
frame for the survey comprised senior researchers in bio-
tech SMEs (small- and medium-sized entrepreneurs) that
were listed in the book "Bio-venture 2007" published by
the Korea Bio Venture Association (KOBIOVEN). The sur-
vey comprised a number of questions with respect to the
effects of upstream discoveries and patented research
tools, including whether the respondents have used pat-
ented research tools, how they have acquired patented
research tools, whether they experienced difficulties in
acquiring patented research tools, what are the major
causes of these difficulties, and what is the main effect of
patents (see Appendix A). The data was analyzed using
statistical methods to assess the researchers' experience in
using research tools and the effects of research tool pat-
ents.
Hypothesis
Research question 1: Concerns: Where do they occur?
This question was posed to determine whether the con-
cerns were more widespread in the biomedical sector than
in other sectors. Many previous studies have only investi-
gated the effects of patents on the biotechnology industry
[7-13], particularly the biomedical sector. If researchers in
the biomedical sector felt a higher level of anxiety with
regard to patents, it would be valid to examine the effects
of patents primarily in this sector. Hence, it was proposed
thatBMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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Hypothesis 1. Researchers who work in the biomedical sector
view the patent system more negatively than researchers in
other sectors.
Research question 2: Does it deter innovation?
Some scholars have surveyed whether research projects
had been changed or abandoned because of difficulties
with prior patents [7,14,15] to determine if "restriction is
a matter of degree." This type of inquiry was a kind of
direct measurement. In this study, we used not only a
direct measurement but also other indirect measurements
such as "attitudes toward patents" and "levels of innova-
tion performance."
If restricted access problems were serious, they would
affect researchers' attitude toward patents. Hence, it was
supposed that
Hypothesis 2. Researchers who experienced difficulties with
prior patents evaluated patents (effects of patents) more nega-
tively.
Indeed, if the restricted access problems were serious, they
would negatively affect the levels of innovation perform-
ance. Hence, it was supposed that
Hypothesis 3. Experiencing difficulties with prior patents and
levels of innovation performance were negatively correlated.
Variables
Participants were asked to choose "the main effect of pat-
ents on innovation" from a list that comprised positive or
negative terms (positive terms: fostering information
sharing, improving productivity; negative terms: increase
in cost, restrictions on access to information, stifling effect
on subsequent innovation). The response terms were then
converted into two categories and given a score of -1 for a
negative term and +1 for a positive term. In addition, par-
ticipants were asked to evaluate "the effects of patents on
innovation." The response scores were then converted to
five response categories and given a score between -2 and
+2 (negative to positive). To determine where the con-
cerns occurred, the scores of two groups (the biomedical
sector vs. other sectors) were compared with each other
using a t-test analysis (see Appendix B). Details of the
compared values are given in Table 1.
If the restricted access problems were serious, they would
affect the researchers' attitude toward patents. To test
whether the restricted access problems were significant,
"the degree of difficulty" in acquiring research tools was
measured by five response categories and given a score of
1 to 5 (very easy to very difficult). Thereafter, the scores
representing "the degree of difficulty" were regressed on
"the effects of patents for innovation" using OLR (ordered
logit regression) (see Appendix B). In this study, corporate
size, proxied by the log number of employees, and corpo-
rate age were used as the control variables. Details of these
variables are given in Table 2.
If the restricted access problems were serious, they would
affect the level of innovation performance. Poisson regres-
sion (see Appendix B) was performed to test the relation-
ship between a firm's innovation performance (proxied
by the total number of patents) and independent varia-
bles that included "the degree of difficulty" in acquiring
research tool patents and two control variables. In this
study, corporate size, proxied by log number of employ-
ees, and corporate age were used as the control variables.
Details of these variables are given in Table 3.
Results and discussion
A total of 109 responses were received (specifically, 39
from the biomedical sector, 36 from the bio-food sector,
15 from the biochemical sector, and 19 from other sec-
tors), which resulted in a response rate of 33.4% (109/
326, see Appendix C).
1. Experience in the Korean biotech SMEs
Use of research tools
In the survey, the participants were asked whether they
had used research tools in their work; 69.7% (76/109) of
the respondents reported that they had done so. As
depicted in Figure 1, most of the respondents who had
used patented research tools acquired them by purchasing
Table 1: Variables (X) considered in t-test analysis
Variable Score Definition
Main effect of patents +1 (positive terms) Fostering information sharing, improving productivity
--1 (negative terms) Increase in costs, restrictions on access to information, stifling effect on 
subsequent innovation
Evaluating effects of patents on innovation --2 ~ +2 --2 = highly negative; --1 = negative;
0 = neither negative nor positive;
+1 = positive; +2 = highly positiveBMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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(53.9%, 41/76), and this method was used most fre-
quently in the bio-food sector (85.0%, 17/20). In addi-
tion, 31.6% (24/76) of the respondents who had used
patented research tools reported that they had made their
own tools. This result was similar to the findings of
another study conducted by Walsh et al. Walsh et al.
found that "one-third of the industrial respondents
acknowledged occasionally using patented research tools
without a license. The firms felt that much of their
research would not yield commercially valuable discover-
ies, and thus, they saw little need to spend money to
secure the rights to use the input technology" [7]. In
Korea, there is a statutory research exemption in patent
law (see Note C), and most of the respondents believed
that this research exemption should be applied more
broadly. The KIPO (Korean Industrial Property Office)
has not yet clearly defined the scope of "research exemp-
tion," but it may be possible to interpret it more narrowly
than what researchers have invoked. In this case, using
patented technologies without permission is considered
as an infringement; thus, there exist other additional
potential problems.
Difficulties in acquiring patented research tools
Participants were asked whether they had experienced dif-
ficulties in acquiring patented research tools. In this sur-
vey, 21.1% (16/76) of the respondents who had used
research tools reported that they had experienced some
difficulties. This was particularly true for researchers in the
biomedical sector, who frequently experienced difficulties
in acquiring patented research tools (31.3%, 10/32).
The most significant issue observed in this study was that
the progress of research was delayed because of the length
of negotiations (50% of the respondents experienced dif-
ficulties, 8/16). Twenty-five percent (4/16) of the
respondents indicated that individual royalties were too
high, while some of the respondents (12.5% of the
respondents experienced difficulties, 2/16) reported that
they were denied the use of patented research tools by pat-
ent owners. In addition, some of the respondents (12.5%
of the respondents experienced difficulties, 2/16)
reported that the negotiations were overly complex (see
Figure 2).
Indeed, 17.1% (13/76) of the respondents who had used
research tools reported that they had to abandon their
projects due to research tool (or upstream discovery) pat-
ents.
These results provided some evidence on the existence of
restricted access problems, even though the frequency was
not high. Furthermore, if a broad scope of the "research
exemption" is not allowed, restricted access problems will
occur more frequently.
Table 2: Variables (X) considered in OLR analysis
Classification Variable Definition
Independent variable Attitude toward patents
(Evaluating effects of patents for innovation)
--2 = highly negative; --1 = negative;
0 = neither negative nor positive;
+1 = positive; +2 = highly positive
Dependent variable Degree of difficulty in acquiring research tools 1 = very easy; 2 = easy; 3 = neither easy nor difficult; 4 = difficult; 5 = very 
difficult
Control variable Size Log number of employees in 2007
Age Number of months until 2007
Table 3: Variables (X) considered in Poisson regression
Classification Variable Definition
Independent variable Innovation performance Total number of patents
Dependent variable Degree of difficulty in acquiring research tools 1 = very easy; 2 = easy;
3 = neither easy nor difficult;
4 = difficult; 5 = very difficult
Control variable Size Log number of employees in 2007
Age Number of months until 2007BMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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Methods for acquiring patented research tools Figure 1
Methods for acquiring patented research tools.
 
 
 
Business field 
Total  
(N = 76) 
Biomedical 
(N = 32) 
Biochemical 
(N = 12) 
Bio-food 
(N = 20) 
Purchase  53.9% (41)  43.8% (14)  50.0% (6)  85.0% (17) 
Manufacturing tools with one’s own 
hand 
31.6% (24)  34.4% (11)  50.0% (6)  10.0% (2) 
License  7.9% (6)  9.4% (3)  0% (0)  5.0% (1) 
Free use after obtaining permission  1.3% (1)  3.1% (1)  0% (0)  0% (0) 
Manufacturing alternative tools  1.3% (1)  3.1% (1)  0% (0)  0% (0) 
MTA  1.3% (1)  3.1% (1)  0% (0)  0% (0) 
Patent not applied in Korea  1.3% (1)  3.1% (1)  0% (0)  0% (0) 
Cross license  1.3% (1)  0% (0)  0% (0)  0% (0) 
 BMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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2. Concerns: Where do they occur?
Participants were asked to choose "the main effect of pat-
ents on innovation" and evaluate "the effects of patents
on innovation." To determine where concerns occur, the
scores of two groups (the biomedical sector vs. other sec-
tors) were compared with each other using a t-test analy-
sis.
The results of this analysis suggest that there were statisti-
cally significant differences between the biomedical sector
and other sectors. As depicted in Table 4, researchers in
the biomedical field evaluated patents more negatively. It
appears that the concerns were more widespread in the
biomedical sector than in other sectors, because follow-on
innovations rely more heavily on prior scientific findings
in this sector than in other sectors; moreover, ethical and
moral issues are associated with patents. These results
Causes of difficulties in using patented research tools Figure 2
Causes of difficulties in using patented research tools.
 
 
Business field 
Total 
(N = 16) 
Biomedical 
(N = 10) 
Biochemical 
(N = 3) 
Bio-food 
(N = 2) 
Research delayed because of 
negotiations 
50.0% (8)  40.0% (4)  100% (3)  0% (0) 
Individual royalties too high  25.0% (4)  40.0% (4)  0% (0)  0% (0) 
Overly complex negotiations  12.5% (2)  10.0% (1)  0% (0)  50% (1) 
Request denied  12.5% (2)  10.0% (1)  0% (0)  50% (1) 
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indicate that it was valid to conduct these types of studies
primarily in the biomedical sector.
3. Does it deter innovation? The current situation
If restricted access problems were serious, they would
affect the researchers' attitude toward patents. To test
whether the restricted access problems were significant,
the scores representing "the degree of difficulty" were
regressed on "attitude toward patents–the effects of pat-
ents for innovation" using OLR. As depicted in Tables 5
and 6, the results obtained from the biotechnology field
were statistically insignificant; however, attitudes toward
patents (evaluating effects of patents) and experiencing
difficulties with prior patents were positively correlated in
the biomedical sector (β = 0.511, p < 0.10). Researchers in
this sector believed that patents had a positive effect on
subsequent innovations (by fostering R&D investment
and information sharing among researchers and improv-
ing research productivity). This indicates that the benefits
of patents are larger than the costs, and the restricted
access problems are not significant. This result is consist-
ent with the results of previous studies [7,10-13].
In addition, if the restricted access problems were serious,
they would adversely affect innovation performance.
Poisson regressions were performed to test the relation-
ship between a firm's innovation performance (proxied
by the total number of patents) and independent varia-
bles that included "the degree of difficulty" in acquiring
research tool patents and two control variables. Descrip-
tive statistics for variables are given in Table 7. As detailed
in Table 8, the degree of difficulty was positively associ-
ated with corporate innovation performance (β = 0.073, p
< 0.05) in the biotechnology industry. In the biomedical
sector, the correlation coefficient between the degree of
difficulty and level of innovation performance was posi-
tive, but the result was statistically insignificant (β =
0.116, p = 0.200; see Table 9). Therefore, we concluded
that the difficulties in acquiring patented research tools
have not yet seriously deterred innovation. This result is
consistent with the results of previous studies [7,10-13].
Conclusions and recommendations for future 
research
Based on the study of the impacts of patents on innova-
tion in the Korean Biotech SMEs and a comparison of
these results with previous studies, we conclude that
although restricted access problems have occurred, this
has not yet deterred innovation in Korea. However, we
Table 4: Where do concerns occur? t-test analysis
Business field N Mean Std. deviation t Df Sig. (2-tailed)
Main Effect*** Biomedical 39 --0.026 1.013 --2.975 67.652 0.004
Others 70 0.543 0.846
Evaluating effects** Biomedical 39 --0.282 0.972 --2.483 107.000 0.015
Others 70 0.143 0.785
*** denotes statistical significance at the < 0.01 level.
** denotes statistical significance at the < 0.05 level.
Table 5: Are "restricted access problems" serious in the 
biotechnology industry? OLR results (1)
Evaluating effects Coeff. Std. err. P > z
Difficulty 0.121 0.189 0.521
Size 0.188 0.475 0.693
Age** 0.014 0.006 0.031
Number of obs. 76
Log likelihood --90.164
LR chi2(3) 6.75
Prob > chi2 0.080
** denotes statistical significance at the < 0.05 level.
Table 6: Are "restricted access problems" serious in the 
biomedical sector? OLR results (2)
Evaluating effects Coeff. Std. err. P > z
Difficulty* 0.511 0.302 0.091
Size --0.151 0.646 0.815
Age** 0.021 0.010 0.038
Number of obs. 32
Log likelihood --39.123
LR chi2(3) 7.32
Prob > chi2 0.063
** denotes statistical significance at the < 0.05 level.
* denotes statistical significance at the < 0.10 level.BMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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can state that potential problems do exist, and the effects
of restricted access should be constantly scrutinized.
This study has some limitations that should be accounted
for in future studies. The biotechnology industry is an
emerging field whose development largely relies on
research-intensive SMEs; thus, in this study, we focused
on biotech SMEs [18]. However, there are other actors of
innovation, for example, universities, public research
institutes, and pharmaceutical firms. Further analysis
should include these actors.
Note A: Instance
"For instance, any scientist who wants to study the genet-
ics of breast cancer needs to utilize the BRCA 1 test." [10]
Note B: Definition of research tools
The NIH (National Institutes of Health) defines research
tools as "embracing the full range of tools that scientists
use in the laboratory." According to the OECD (Organiza-
tion for Economic Cooperation and Development),
"research tools may be considered compositions or meth-
ods used in conducting experiments. This term could
embrace a broad range of resources that scientists use in
the laboratory including, but not limited to, cell lines,
monoclonal antibodies, reagents, animal models, growth
factors, combinational chemistry, genomic and pro-
teomic libraries, drug and drug targets, clones and cloning
tools, methods, laboratory equipment and machines,
databases and software."
Note C: Related section
"The effects of the patent right shall not extend to the fol-
lowing: (i) working of the patented invention for the pur-
pose of research or experiment..." (Section 96-(1) of the
Patent Law in Korea).
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formed the statistical analysis, and drafted the manu-
script. TR also participated in the design of the survey. YL
conceived the study and helped in drafting the manu-
script. All authors read and approved the final manu-
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Appendix A: Questionnaire
Q1. What is the main business field of your company?
1) Biomedical 2) Biochemical 3) Bio-food 4) Bio-envi-
ronment
Table 7: Descriptive statistics and correlation (n = 76)
Mean S. D. Difficulty Size Age
Difficulty 2.566 1.159 1.000
Size 1.276 0.473 0.030 1.000
Age 95.658 38.037 --0.091 0.357 1.000
Table 8: Restricted access problems and innovation performance 
in the biotechnology industry: Poisson regression results of 
variables versus innovation performance
Innovation performance Coeff. Std. err. P > z
Constant*** 1.377 0.266 0.000
Difficulty** 0.073 0.034 0.033
Size* 0.290 0.171 0.090
Age 0.003 0.002 0.242
Sigma 0.826 0.048 0.000
Number of obs. 76
Log likelihood --856.413
Chi squared 1121.803
Prob > chi2 0.000
Poisson model with normal heterogeneity
*** denotes the correlation coefficient observed at significance level < 
0.01.
** denotes the correlation coefficient observed at significance level < 
0.05.
* denotes the correlation coefficient observed at significance level < 
0.10.
Table 9: Restricted access problems and innovation performance 
in the biomedical sector: Poisson regression results of variables 
versus innovation performance
Innovation performance Coeff. Std. err. P > z
Constant** 1.289 0.612 0.035
Difficulty 0.116 0.091 0.200
Size 0.156 0.352 0.657
Age 0.004 0.006 0.512
Sigma 0.862 0.094 0.000
Number of obs. 32
Log likelihood --128.999
Chi squared 678.769
Prob > chi2 0.000
Poisson model with normal heterogeneity
** denotes the correlation coefficient observed at significance level < 
0.05.BMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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5) Bio-energy 6) Bio-electronics 7) Bio-process 8) Bio-
informatics
Research tools embrace the full range of tools that sci-
entists use in the laboratory. This term includes, but
not limited to, cell lines, monoclonal antibodies, rea-
gents, animal models, growth factors, combinational
chemistry, genomic and proteomic libraries, drug and
drug targets, clones and cloning tools, methods, labo-
ratory equipment and machines, databases, and soft-
ware. Patented research tools are research tools
protected by patent law.
Q2. Have you used any patented research tools in your
research? (Please answer within the context of your
employment.)
1) Yes 2) No
Q3. Which of the following methods was mainly used in
the acquisition of the patented research tools?
1) Manufacturing tools with one's own hand
2) Manufacturing alternative tools
3) Purchase
4) Free use after obtaining permission
5) License
6) Cross-license
7) Material Transfer Agreement (MTA)
8) Free use because the patent(s) is (are) not applied
in Korea
9) Other ___________________________________
Q4. How easy or difficult was it to acquire the patented
research tools?
1) Very easy 2) Easy 3) Neither easy nor difficult
4) Difficult 5) Very difficult
Q5. If you had experienced difficulties, what was the main
reason?
1) Research was delayed because of negotiations
2) Individual royalties were too high
3) Overly complex negotiations
4) Royalty stacking
5) Licensing negotiations broke down
6) Requests denied
7) Unable to determine the patent status of the
research tool
8) Other ____________________________________
Q6. Has your research been changed due to patented
research tools or prior upstream discoveries?
1) Yes 2) No
Q7. Has your research been abandoned due to patented
research tools or prior upstream discoveries?
1) Yes 2) No
Q8. What do you think is the main effect of patented
research tools or prior upstream discoveries?
1) Fostering information sharing among researchers
2) Improving research productivity
3) Increasing research cost
4) Restricting access to information
5) Stifling effect on subsequent innovation
6) Other ________________________________
Q9. Please evaluate the effects of patents on innovation
1) Positive effect: _______ % + 2) Negative effect:
_______ % = 100%
Q10. Has your company applied for patents? 1) Yes 2) No
If yes, how many patents have been applied for?
_______________
Appendix B: Statistical models
An independent t-test analysis was used to investigate
hypothesis 1 by comparing the differences in attitudes of
scientists in biomedical and other fields toward the patent
system. The t-test was used to compare the values of the
means from two samples and to test whether it is likely
that the samples are from populations having differentBMC Biotechnology 2009, 9:25 http://www.biomedcentral.com/1472-6750/9/25
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mean values [19]. The formula for the independent t-test
is
where X1 denotes the mean for group 1; X2, the mean for
group 2; SS1, the sum of squares for group 1; SS2, the sum
of squares for group 2; n1, the number of subjects in group
1; and n2, the number of subjects in group 2.
An OLR model and Poisson regression model were used
to investigate hypotheses 2 and 3: Does it deter innova-
tion? The current situation.
The OLR is used when the variables are ordinal dependent
variables [20]. The ordered logit model has the following
form:
The data for the number of scientific publications falls in
the category of count data. The Poisson regression model
has been widely used to study such data [21]. The primary
equation of this model is
The most common formulation for λi is the log-linear
model,
ln λi = β'Xi
The variables were regressed on a set of factors integrated
into the equation.
Appendix C: A note on the interpretation of 
statistics
The response rate for the survey was 34.4%. The low r
esponse rate could have caused unmeasured bias in the
statistics given in this manuscript. To address this issue,
the main characteristics of the companies that responded
to the survey were compared with those of the companies
that did not respond to determine if our results represent
a biased subset. All the companies were listed in the book
"Bio-venture 2007" published by KOBIOVEN.
On the basis of this analysis, we found that the companies
that responded and the companies that did not respond
had a similar age, numbers of employees and patents, and
similar distributions in the business field. These results
indicate that the low response rate of our survey did not
induce a bias (see Table 10).
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Table 10: Comparing respondents and nonrespondents
Main Characteristics Respondents Nonrespondents Sig.
Age 7.9 yr 7.3 yr n.s.
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Number of patents 9.0 8.4 n.s.
Business fields
Biomedical field 35.8% 28.6% n.s.
Biochemical field 13.8% 15.7% n.s.
Bio-food field 33.0% 23.5% n.s.
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